GLP-1 & Hidradenitis Suppurativa: Research Guide

If you live with hidradenitis suppurativa (HS), you have probably heard about GLP-1 receptor agonists. These medications are reshaping how clinicians manage obesity and type 2 diabetes, and patients are asking whether they could also help HS. The honest answer is more nuanced than a headline. This guide explains what HS is, why the GLP-1 question keeps coming up, what the dermatology and HS literature actually says, and how to think about next steps with a clinician.

What Is Hidradenitis Suppurativa?

Hidradenitis suppurativa is a chronic, recurrent inflammatory disease of the hair follicle. It most often affects apocrine gland-bearing areas such as the armpits, groin, under the breasts, and the buttocks. Patients develop painful nodules, abscesses, draining sinus tracts, and scarring. The condition is not a bacterial infection, a hygiene problem, or an isolated skin issue. It is understood as a follicular occlusion disorder with dysregulated immune signaling that drives inflammation and tissue destruction [PMID 39862870](https://pubmed.ncbi.nlm.nih.gov/39862870/), [PMID 31604104](https://pubmed.ncbi.nlm.nih.gov/31604104/), [PMID 32165620](https://pubmed.ncbi.nlm.nih.gov/32165620/).

Symptoms often begin after puberty and can persist for decades, with flares and remissions. The disease burden extends beyond skin. Pain, odor, drainage, and scarring can affect work, relationships, exercise, and mental health. Because HS can be mistaken for boils or cysts, it is frequently underdiagnosed or diagnosed years after symptoms begin. Pediatric presentations also occur, and early recognition matters because delayed treatment can lead to more extensive scarring [PMID 37102307](https://pubmed.ncbi.nlm.nih.gov/37102307/).

Pathogenesis and Systemic Inflammation

Modern understanding of HS centers on follicular occlusion followed by rupture and a robust inflammatory response. Innate immune signaling, Th1 and Th17 cytokine pathways, and adipose tissue inflammation all appear to play roles [PMID 40023620](https://pubmed.ncbi.nlm.nih.gov/40023620/), [PMID 33058306](https://pubmed.ncbi.nlm.nih.gov/33058306/). The exact trigger remains unclear. Genetics, smoking, hormonal factors, and mechanical friction are all suspected contributors in susceptible individuals.

What makes HS clinically important is that it is not only a skin disease. It is associated with obesity, metabolic syndrome, insulin resistance, polycystic ovary syndrome, depression, inflammatory bowel disease, and other systemic conditions [PMID 31604104](https://pubmed.ncbi.nlm.nih.gov/31604104/), [PMID 39862870](https://pubmed.ncbi.nlm.nih.gov/39862870/). This systemic framing is why a comprehensive evaluation often includes weight, metabolic labs, smoking status, and mental health screening rather than treating lesions in isolation.

Standard Care and Treatment Goals

HS management is staged and individualized. For mild disease, topical therapies and short courses of oral antibiotics may be used. For moderate to severe disease, clinicians may consider oral anti-inflammatory agents, hormonal therapies, biologic medications such as adalimumab, and surgical procedures in selected cases [PMID 39862870](https://pubmed.ncbi.nlm.nih.gov/39862870/), [PMID 37236715](https://pubmed.ncbi.nlm.nih.gov/37236715/). Lifestyle measures, including smoking cessation and weight management, are consistently emphasized because they address modifiable risk factors.

The goal of treatment is not cure. HS is a chronic condition. The goal is control: reducing the number of nodules, limiting drainage and pain, minimizing scarring, and improving quality of life. Patients are usually managed long-term with a combination of medical, procedural, and lifestyle strategies.

Why Patients Ask About GLP-1 Receptor Agonists

GLP-1 receptor agonists, including semaglutide and tirzepatide, are approved for type 2 diabetes and obesity. They improve glycemic control, promote weight loss, and have cardiovascular benefits in selected populations. Their rapid visibility has led patients with many conditions to ask whether they might help HS. The question is reasonable for three reasons.

First, weight and HS are linked. Obesity is a recognized risk factor and common comorbidity. Excess weight increases friction in skin folds and is associated with insulin resistance and low-grade inflammation, all of which may worsen HS expression. Weight reduction is a recognized supportive component of HS management [PMID 31604104](https://pubmed.ncbi.nlm.nih.gov/31604104/).

Second, metabolic disease clusters with HS. Many patients with HS have prediabetes, type 2 diabetes, or metabolic syndrome. Treating those conditions is part of whole-person care, even if it does not directly clear HS lesions. GLP-1 agonists are one tool for metabolic management in appropriate candidates.

Third, there is scientific curiosity about whether GLP-1 signaling affects immune pathways relevant to HS. Preclinical research has explored GLP-1 effects on inflammation, but translation to human HS outcomes is not established. This gap between biological plausibility and clinical evidence is where misinformation tends to grow.

What the Dermatology Literature Says About GLP-1 and Skin

A 2025 review, "A Closer Look at the Dermatological Profile of GLP-1 Agonists," examines how GLP-1 receptor agonists intersect with dermatologic conditions [PMID 40422559](https://pubmed.ncbi.nlm.nih.gov/40422559/). As use of these medications has expanded, dermatologists are evaluating whether they may influence skin disease expression, including inflammatory conditions. The review reflects a growing awareness that GLP-1 agonists should be assessed not only for metabolic outcomes but also for their dermatologic profile.

It is important to state clearly: hidradenitis suppurativa is not an approved indication for GLP-1 receptor agonists. No large randomized controlled trial has established that GLP-1 medications improve HS-specific outcomes. The current evidence consists of mechanistic speculation, indirect benefits through weight or metabolic improvement, and limited clinical observations that require cautious interpretation. Any use of GLP-1 therapy for HS would be off-label and should be individualized under medical supervision.

What We Do Not Know

The list of unknowns is longer than the list of knowns. There is no established dosing protocol for GLP-1 agonists in HS. There is no validated monitoring plan for HS flares or response. It is unclear whether any benefit would come from weight loss, metabolic improvement, direct anti-inflammatory effects, or a combination. It is also unclear whether GLP-1 therapy could in some cases aggravate skin conditions, as dermatologic adverse events have been reported with these medications and require careful evaluation [PMID 40422559](https://pubmed.ncbi.nlm.nih.gov/40422559/).

Because HS is heterogeneous, what helps one patient may not help another. A medication that addresses obesity may indirectly improve HS in a patient with significant metabolic disease but offer little to a lean patient without metabolic risk factors. That is why blanket recommendations are not appropriate.

Practical Questions Patients Ask

Can a GLP-1 medication cure my HS? No. HS is a chronic condition with no known cure. GLP-1 agonists are not approved for HS and should not be viewed as a cure.

Could weight loss help my HS? Weight loss is a recognized supportive measure for HS. It may reduce friction and improve metabolic parameters. However, it is not a standalone treatment and does not replace medical or procedural HS therapy [PMID 31604104](https://pubmed.ncbi.nlm.nih.gov/31604104/).

Should I ask my doctor about a GLP-1 drug for my HS? You should discuss it if you have obesity, prediabetes, type 2 diabetes, or metabolic syndrome alongside HS. A licensed clinician can evaluate whether the medication is appropriate for your overall health, not only your skin.

Are there risks to GLP-1 agonists? Yes. Common adverse effects include nausea, vomiting, diarrhea, and constipation. More serious risks include gallbladder disease, pancreatitis, and rare thyroid safety concerns in patients with personal or family history of medullary thyroid carcinoma or MEN2. Eligibility and monitoring must be determined by a clinician.

Does inflammation matter in HS? Yes. HS is fundamentally an inflammatory disease. The immune dysregulation seen in HS is well documented [PMID 40023620](https://pubmed.ncbi.nlm.nih.gov/40023620/). However, not all anti-inflammatory pathways are best treated with the same drug. Approved HS therapies target specific cytokine pathways, and GLP-1 agonists do not currently have an established role in that pathway.

Summary Table: Evidence and Gaps

How LuxeFit Wellness Approaches This

At LuxeFit Wellness, we serve DFW-first patients through cash-pay virtual care. For patients with HS or suspected HS, we use structured clinician-guided intake and follow-up to evaluate symptoms, comorbidities, and whether metabolic therapies are appropriate. We do not prescribe GLP-1 medications for HS as a standalone indication. We do review whether weight or metabolic management may be clinically appropriate alongside dermatology-coordinated care. If you are already on a GLP-1 medication and notice skin changes, we can help you understand when to raise the issue with your prescribing clinician.

Closing

GLP-1 receptor agonists are an important medication class for obesity and metabolic disease, but they are not established therapy for hidradenitis suppurativa. The connection between the two is biologically plausible and clinically interesting, yet it remains speculative. If you have HS and are curious about GLP-1 medications, the right next step is a clinician consultation that reviews your full medical history, current HS treatments, metabolic profile, and personal goals.

---

Disclaimer

This article is educational and not medical advice. Care decisions, eligibility, dosing, contraindications, and monitoring require a licensed clinician. If you are experiencing HS symptoms, consult a dermatologist or qualified healthcare provider before starting, stopping, or changing any medication.

References

[Persson C et al. — A Closer Look at the Dermatological Profile of GLP-1 Agonists](https://pubmed.ncbi.nlm.nih.gov/40422559/)

[Sabat R et al. — Hidradenitis suppurativa (Lancet)](https://pubmed.ncbi.nlm.nih.gov/39862870/)

[Goldburg SR et al. — Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis](https://pubmed.ncbi.nlm.nih.gov/31604104/)

[Jenkins T et al. — Hidradenitis Suppurativa (Dermatologic clinics)](https://pubmed.ncbi.nlm.nih.gov/37236715/)

[Sabat R et al. — Hidradenitis suppurativa (Nature reviews Disease primers)](https://pubmed.ncbi.nlm.nih.gov/32165620/)

[Cotton CH et al. — Hidradenitis Suppurativa in Pediatric Patients](https://pubmed.ncbi.nlm.nih.gov/37102307/)

[Zouboulis CC et al. — What causes hidradenitis suppurativa?-15 years after](https://pubmed.ncbi.nlm.nih.gov/33058306/)

[Pham J et al. — Hidradenitis Suppurativa: Pathogenesis and Inflammatory Pathways](https://pubmed.ncbi.nlm.nih.gov/40023620/)